低风险甲状腺乳头状微小癌主动监测的分子特征分析
研究对前瞻性纳入主动监测程序的95份细针穿刺细胞学标本行二代测序,分析低风险甲状腺乳头状微小癌的驱动突变与基因融合。BRAF p.V600E最常见(66.3%),RAS突变和基因融合各占3.2%,未检出TERT启动子突变。分子特征与疾病进展无相关性(P = .6),未能识别进展病例的分子标志。
要点
- 低风险甲状腺乳头状微小癌中BRAF p.V600E检出率为66.3%(63/95),为最常见体细胞变异。
- RAS突变和基因融合各检出3.2%(3/95),84/95例未检出TERT启动子突变。
- 分子特征与稳定 versus 进展的临床结局无相关性(P = .6)。
核心结论
- 低风险甲状腺乳头状微小癌的分子特征与较大甲状腺乳头状癌相似,但均未检出TERT启动子突变。
- BRAF、RAS或基因融合等常见驱动突变的识别无助于早期识别主动监测随访中会进展的病例。
研究设计与样本
- 对前瞻性纳入主动监测程序的95份细针穿刺细胞学标本行二代测序,分析甲状腺乳头状癌肿瘤发生相关的关键体细胞驱动变异或基因融合。
- TERT启动子分析采用Sanger测序或微滴数字聚合酶链反应。
主要发现
- BRAF p.V600E在66.3%(63/95)的低风险甲状腺乳头状微小癌中检出,为最常见体细胞变异。
- RAS癌基因突变检出3.2%(3/95:2例NRAS和1例KRAS),基因融合检出3.2%(3/95:1例RET-PTC1、1例TFG-NTRK1、1例ALK失衡)。
- 分析的84/95例低风险甲状腺乳头状微小癌中未检出TERT启动子突变(C228T和C250T)。
- 分子特征与临床结局(稳定 versus 进展)比较无相关性(P = .6),未识别出能识别进展性低风险甲状腺乳头状微小癌的分子标志。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The active surveillance (AS) program for papillary thyroid carcinoma (≤1 cm) at low risk (mPTC) showed a low percentage of progression. OBJECTIVE: The aim of this study was to find a molecular signature of cases that showed disease progression during AS, which would allow their early identification. METHODS: We performed next-generation sequencing of 95 fine-needle aspiration cytology specimens from cases prospectively enrolled in the AS program to analyze key somatic driver alterations or gene fusions implicated in PTC tumorigenesis. TERT promoter analysis was performed using Sanger sequencing or droplet digital polymerase chain reaction. RESULTS: BRAF p.V600E was found in 66.3% (63/95) of mPTC and was the most common somatic alteration, followed by RAS oncogene mutations detected in 3.2% of mPTC (3/95: 2 NRAS and 1 KRAS) and gene fusions detected in 3.2% of mPTC (3/95: 1 RET-PTC1, 1 TFG-NTRK1, 1 ALK imbalance). No TERT promoter mutations (C228T and C250T) were found in the analyzed mPTC (84/95). The comparison between the molecular profile and the clinical outcome of the mPTC (stable vs progressive disease) showed no correlation (P = .6) and did not identify a molecular signature able to identify progressive mPTC. CONCLUSION: The molecular profile of mPTC is like that of bigger PTC with the exception that none of them showed a TERT promoter mutation. The identification of the most common driver mutations, such as BRAF, RAS, or gene fusions, is not helpful for the early identification of mPTC that will show disease progression during follow-up in the AS program.
引用
- Ramone T, Ghirri A, Prete A, et al. Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. J Clin Endocrinol Metab. 2025. PMID: 39180363. doi:10.1210/clinem/dgae575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。